Prøve GULL - Gratis

Bio Spectrum - May 2023

filled-star
Bio Spectrum

Gå ubegrenset med Magzter GOLD

Lese Bio Spectrum sammen med 9000+ andre magasiner og aviser med bare ett abonnement  

Se katalog

1 måned

$14.99

1 år

$149.99

$12/month

(OR)

Abonner kun på Bio Spectrum

Kjøp denne utgaven: May 2023

1 problemer som starter fra May 2023

12 problemer som starter fra May 2023

Kjøp denne utgaven

$0.99

1 år

$10.99

Please choose your subscription plan

Avbryt når som helst.

(Ingen forpliktelser) ⓘ

Hvis du ikke er fornøyd med abonnementet, kan du sende oss en e-post på help@magzter.com innen 7 dager etter abonnementets startdato for full refusjon. Ingen spørsmål - lover! (Merk: Gjelder ikke for enkeltutgavekjøp)

Digitalt abonnement

Øyeblikkelig tilgang ⓘ

Abonner nå for å begynne å lese umiddelbart på Magzter-nettstedet, iOS, Android og Amazon-appene.

Verifisert sikker

betaling ⓘ

Magzter er en verifisert Authorize.Net-forhandler. Les mer

I dette nummeret

Could 7.5% R&D Spends Make India PHARMA INNOVATION HUB?
Areport by India Brand Equity Foundation (IBEF) stated that India’s domestic pharmaceutical market was estimated at $42 billion in 2021, which is likely to reach $ 65 billion by 2024 and may further expand to reach nearly $120-130 billion by 2030. The country’s vast pool of scientific talent, strong system of higher education, low operating costs, conducive regulatory environment and supportive government
policies have made it an attractive destination for drug development, clinical trials, and commercial manufacturing. A growing population, significant R&D investments, a modernised manufacturing base and the prevalence of chronic diseases have fuelled the growth of the pharma sector. And the backbone of the success can be largely attributed to robust R&D measures in recent years. Post COVID-19, pharma players have increased their R&D investment.

Bio Spectrum Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.

Nylige utgaver

Spesielle problemer

  • March 2013

    March 2013

Relaterte titler

Populære kategorier